Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › DD1013

DD1013

GLP-1 + GIP + amylin (triple) · s.c. · Huadong Medicine

Data cut 12 November 2026 · page built 16 November 2026 · 0 trial arms · 0 trials with results · 0 registered trials · see on the pipeline board

Summary

Also known as
Huadong
Mechanism
GLP-1 + GIP + amylin (triple)
Route
s.c.
Company
Huadong Medicine
Highest development stage
preclinical
Status (as of data cut)
Preclinical (EASD 2026) verify
Next milestone
Phase 1

Trial arms: weight, HbA1c and tolerability

No trial arms with extracted efficacy or tolerability data yet.

Primary sources

No source recorded.

How to cite this page

Medical Adviser's Group. Incretin Atlas: DD1013. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/dd1013/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.